Home/ Stocks/ CMPX

Compass Therapeutics, Inc. Common Stock

CMPX XNAS

$2.15 +0.17 (+8.54%) ▲ 15-min delayed

Open

$2.05

High

$2.17

Low

$2.03

Volume

3.83M

Market Cap

$358.37M

About Compass Therapeutics, Inc. Common Stock

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 39 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-18,317,000	$-0.10
FY 2025	$0	$-66,489,000	$-0.42
Q3 2025	$0	$-14,259,000	$-0.08
Q2 2025	$0	$-19,881,000	$-0.14

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for CMPX yet. Check out our latest market news or earnings calendar.

Get CMPX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Compass Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.